Samsung Biologics Receives Frost & Sullivan Institute's 'Innovation Growth Leadership Award'

Samsung Biologics Plant 3 exterior view.

[Asia Economy Reporter Lee Gwan-joo] Samsung Biologics announced on the 10th that it received the '2022 Innovation Growth Leadership Award' from the Frost & Sullivan Institute.

The Frost & Sullivan Institute is a nonprofit organization under the global market research firm Frost & Sullivan, which annually selects companies that have achieved innovative results and played a significant role in realizing a sustainable society through CSR (Corporate Social Responsibility) and ESG (Environmental, Social, and Governance) related activities.

Samsung Biologics has established an 'end-to-end' contract development and manufacturing organization (CDMO) business, covering from the early stages of biopharmaceuticals to commercial production, through proactive and bold investments within a short period. Within seven years of entering the business, it built three plants securing the world's largest production capacity, and with the completion of Plant 4 next year, which is the largest single plant, it is expected to account for about 30% of global CDMO production volume.

Along with this, Samsung Biologics has taken the lead in facilitating the global production and supply of biopharmaceuticals by expanding its business portfolio to include mRNA. In particular, during the COVID-19 pandemic, it contributed to resolving vaccine shortages by rapidly and stably producing vaccines and antibody therapeutics developed by global pharmaceutical companies such as Moderna, AstraZeneca, and Eli Lilly. Recently, it established mRNA drug substance (DS) production facilities and produced COVID-19 mRNA vaccines for GreenLight Biosciences in the United States, supporting the expansion of vaccine distribution in underdeveloped countries.

The Frost & Sullivan Institute stated, "Samsung Biologics has greatly contributed to improving human health by collaborating with global clients to produce vaccines and therapeutics," and added, "We recognize Samsung Biologics' dedication to reducing global diseases, carbon emissions, and industrial accidents to zero through a scientific approach."

John Rim, CEO of Samsung Biologics, said, "We are pleased that Samsung Biologics' efforts to solve global challenges together as a global CDMO partner have been recognized," and added, "We will continue to do our best to help create a sustainable future through more innovative and bold challenges in the biopharmaceutical industry."